Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China; National Center for Safety Evaluation of Drugs, National Institute for Food and Drug Control, Key Laboratory of Beijing for Nonclinical Safety Evaluation of Drugs, A8 Hongda Middle Street, Beijing Economic-Technological Development Area, Beijing, 100176, China.
National Center for Safety Evaluation of Drugs, National Institute for Food and Drug Control, Key Laboratory of Beijing for Nonclinical Safety Evaluation of Drugs, A8 Hongda Middle Street, Beijing Economic-Technological Development Area, Beijing, 100176, China.
J Ethnopharmacol. 2019 Jul 15;239:111910. doi: 10.1016/j.jep.2019.111910. Epub 2019 Apr 23.
Xian-Ling-Gu-Bao (XLGB) Fufang is an herbal formula that has been used in clinical settings to treat osteoporosis, osteoarthritis, aseptic bone necrosis, and climacteric syndrome. Despite its uses, XLGB treatment has been linked to potential liver injury. To date, there is a lack of clear demonstration of such toxicity in animal models.
As animal models fail to reproduce the XLGB hepatotoxicity reported in humans, because human hepatocytes are clearly more sensitive to XLGB, this study was designed to investigate a more reliable animal model of such toxicity.
We randomized rats into five groups, as follows: CON (control), XLGB, lipopolysaccharide (LPS), L-XLGB/LPS (XLGB, 0.125 g/kg; LPS, 0.1 mg/kg), and XLGB/LPS (XLGB, 1.25 g/kg; LPS, 0.1 mg/kg). These groups were treated with 0.5% sodium carboxymethyl cellulose (CMC-Na), XLGB suspension, normal saline, or LPS. The first administration of XLGB [0.125 g/kg or 1.25 g/kg, by mouth (PO)] or its solvent (0.5% CMC-Na) was delivered, and then food was removed. Twelve hours after the first administration of XLGB, rats received LPS [0.1 mg/kg, intravenously (IV)] or saline control. After 30 min, a second administration of XLGB (0.125 g/kg or 1.25 g/kg, PO) or solvent was administered. The rats were anesthetized at 12 h or 24 h following the second administration of XLGB. Liver function was evaluated by measuring liver weight, liver microscopy, serum biochemistry and plasma microRNA-122 (miR-122). The plasma levels of 27 cytokines were measured to evaluate inflammation. Moreover, the expression of cytochrome P450 2E1 (CYP2E1), nicotinic adenine dinucleotide phosphate (NADPH) oxidase and inducible nitric oxide synthase (iNOS) at protein levels were observed; immunofluorescence and immunohistochemistry were used to confirmed the hepatotoxicity of XLGB.
Hepatotoxicity in male rats with moderate inflammation induced by XLGB was indicated by liver histopathology, serum biochemical analysis, serum miR-122 levels, and immunofluorescent assessments. We observed significant increases in liver weight and liver indexes in male rats with moderate inflammation in response to XLGB. Histopathological assessment further showed that extensive hepatocellular necrosis and inflammatory infiltration were evident in rats co-treated with XLGB/LPS. The levels of serum transaminases [alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT)], total bilirubin (TBIL) and triglyceride (TG), which are markers of liver function, were also significantly increased by XLGB/LPS treatment. Similarly, miR-122 was significantly elevated in XLGB/LPS treated rats relative to other groups. An immunofluorescent assessment showed extensive apoptosis in hepatocytes from these co-treated rats. What is more, XLGB can dose-dependently induce liver injury in male rats with moderate inflammation. Hepatic CYP2E1, neutrophil chemotactic factor (NCF-1), iNOS, and NOX-2 (an NADPH oxidase subunit) levels were increased in response to XLGB treatment, and staining for DMPO nitrone adducts further showed elevated oxidative stress level in XLGB/LPS-treated rats relative to the other experimental groups.
LPS and XLGB co-treatment in rats led to marked hepatotoxicity. This toxicity was associated with disrupted lipid metabolism, extensive liver necrosis and inflammatory infiltration, apoptosis, and expression of oxidative stress-related proteins. These results demonstrate a valuable model for the study of iDILI in the context of XLGB treatment, and further provide insights into the potential mechanisms by which XLGB may induce hepatotoxicity in humans.
仙灵骨葆(XLGB)复方已在临床环境中用于治疗骨质疏松症、骨关节炎、无菌性骨坏死和更年期综合征。尽管有其用途,但 XLGB 治疗与潜在的肝损伤有关。迄今为止,在动物模型中缺乏对这种毒性的明确证明。
由于动物模型无法再现人类报告的 XLGB 肝毒性,因为人类肝细胞显然对 XLGB 更为敏感,因此本研究旨在设计一种更可靠的动物模型来研究这种毒性。
我们将大鼠随机分为五组:CON(对照组)、XLGB、脂多糖(LPS)、L-XLGB/LPS(XLGB,0.125g/kg;LPS,0.1mg/kg)和 XLGB/LPS(XLGB,1.25g/kg;LPS,0.1mg/kg)。这些组分别用 0.5%羧甲基纤维素钠(CMC-Na)、XLGB 混悬液、生理盐水或 LPS 处理。首先给予 XLGB [0.125g/kg 或 1.25g/kg,口服(PO)]或其溶剂(0.5%CMC-Na),然后去除食物。第一次给予 XLGB 后 12 小时,大鼠接受 LPS [0.1mg/kg,静脉内(IV)]或生理盐水对照。30 分钟后,给予第二次 XLGB(0.125g/kg 或 1.25g/kg,PO)或溶剂。第二次给予 XLGB 后 12 小时或 24 小时,大鼠被麻醉。通过测量肝重、肝显微镜、血清生物化学和血浆 microRNA-122(miR-122)来评估肝功能。测量 27 种细胞因子的血浆水平以评估炎症。此外,观察细胞色素 P450 2E1(CYP2E1)、烟酰胺腺嘌呤二核苷酸磷酸(NADPH)氧化酶和诱导型一氧化氮合酶(iNOS)的蛋白水平表达;免疫荧光和免疫组织化学用于确认 XLGB 的肝毒性。
XLGB 引起的雄性大鼠中度炎症引起的肝毒性,通过肝组织病理学、血清生化分析、血清 miR-122 水平和免疫荧光评估来表明。我们观察到,中度炎症的雄性大鼠肝重和肝指数显著增加,对 XLGB 有反应。组织病理学评估进一步表明,XLGB/LPS 共同治疗的大鼠中广泛存在肝细胞坏死和炎症浸润。血清转氨酶[丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、γ-谷氨酰转移酶(GGT)]、总胆红素(TBIL)和甘油三酯(TG)等肝功能标志物的水平也因 XLGB/LPS 治疗而显著升高。同样,miR-122 在 XLGB/LPS 治疗的大鼠中也明显升高。免疫荧光评估显示,这些共同治疗的大鼠肝细胞广泛凋亡。更重要的是,XLGB 可以在雄性大鼠中度炎症中呈剂量依赖性地诱导肝损伤。肝 CYP2E1、中性粒细胞趋化因子(NCF-1)、iNOS 和 NADPH 氧化酶亚基(NOX-2)水平随 XLGB 治疗而增加,DMPO 硝酮加合物的染色进一步显示 XLGB/LPS 治疗组大鼠的氧化应激水平高于其他实验组。
LPS 和 XLGB 联合处理大鼠导致明显的肝毒性。这种毒性与脂质代谢紊乱、广泛的肝坏死和炎症浸润、细胞凋亡以及氧化应激相关蛋白的表达有关。这些结果证明了一种有价值的模型,可用于研究 XLGB 治疗中 iDILI,并进一步提供了关于 XLGB 可能导致人类肝毒性的潜在机制的见解。